These data suggest that targeting KRAS and downstream effectors on both a protein and an mRNA level can improve tumor burden and overall survival for a more extended period, highlighting a potential combination approach of targeting mutant KRAS protein as well as KRAS and MYC mRNA. This evidence concerns the gene KRAS and neoplasm.